CTHRC1 and Its Role in Cancer Prognosis and Drug Resistance
Author Information
Author(s): Zhang Rumeng, Wang Zhihao, Wang Huan, Li Lin, Dong Lin, Ding Lin, Li Qiushuang, Zhu Linyan, Zhang Tiantian, Zhu Yong, Ding Keshuo
Primary Institution: Anhui Medical University
Hypothesis
Is CTHRC1 expression associated with the BRAF(V600E) mutation and does it correlate with prognosis and drug resistance in colon cancer, thyroid cancer, and melanoma?
Conclusion
CTHRC1 expression is significantly associated with the BRAF(V600E) mutation and correlates with poor prognosis and drug resistance in colon cancer and thyroid cancer, but not in melanoma.
Supporting Evidence
- CTHRC1 expression was positively correlated with the BRAF(V600E) mutation in colon cancer and thyroid cancer.
- High CTHRC1 levels were associated with poor overall survival in colon and thyroid cancer patients.
- CTHRC1 expression correlated with immune cell infiltration in colon and thyroid cancers.
- Patients with high CTHRC1 expression showed decreased sensitivity to BRAF(V600E) targeted drugs.
Takeaway
CTHRC1 is a protein that can help doctors understand how serious colon and thyroid cancers are and how well treatments might work.
Methodology
The study involved database analysis and clinical tissue studies, including RNA-seq data and qRT-PCR to assess CTHRC1 expression.
Limitations
The study primarily focused on three cancer types and may not generalize to other cancers.
Participant Demographics
Included patients with colon cancer, thyroid cancer, and melanoma, with specific mutations analyzed.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website